Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Primary ADT proves ineffective in early stage prostate cancer patients

Primary ADT proves ineffective in early stage prostate cancer patients

A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment. [More]
iCAD prices underwritten public offering of 2,400,000 shares of common stock

iCAD prices underwritten public offering of 2,400,000 shares of common stock

iCAD, Inc. ("iCAD"), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has priced a registered firm commitment underwritten public offering of 2,400,000 shares of its common stock at a price to public of $11.00 per share. [More]

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

The Medical University of South Carolina (MUSC), one of the nation's top academic health science centers, and Alliance Oncology, a division of Alliance HealthCare Services, Inc., announce a newly formed affiliation designed to strengthen and expand MUSC's Hollings Cancer Center as the radiation therapy market leader in Charleston, South Carolina. [More]
Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO. [More]
Important facts about colorectal cancer

Important facts about colorectal cancer

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years. [More]
Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013. [More]
Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company that is developing a new class of cancer drugs, are renewing their partnership. [More]

Mcl-1 protein enables NSCLC to survive radiation and drug treatments

Researchers at the Translational Genomics Research Institute have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments. [More]

UNM physician performs TORS procedure on patient with stage IV throat cancer

When Charlie Guinn sits down to eat with his lovely wife of 39 years, he thoroughly enjoys each bite. It's not just the food; the entire experience is a celebration. Just over a year ago, Mr. Guinn learned that he had stage IV throat cancer. [More]
Yoga offers unique benefits for women with breast cancer undergoing radiation therapy

Yoga offers unique benefits for women with breast cancer undergoing radiation therapy

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to research from The University of Texas MD Anderson Cancer Center. [More]
Scientists uncover key mechanism of gene regulation

Scientists uncover key mechanism of gene regulation

In the cells of humans and other organisms, only a subset of genes are active at any given time, depending largely on the stage of life and the particular duties of the cell. Cells use different molecular mechanisms to orchestrate the activation and deactivation of genes as needed. [More]

Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWBC

Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer. [More]

Robotic-assisted radical prostatectomy shows better outcomes in cancer removal

An observational study from UCLA's Jonsson Comprehensive Cancer comparing robotic-assisted prostate surgery to open surgery for prostate cancer found that patients who had robotic surgery had fewer instances of cancer cells at the edge of the surgical specimen, or fewer positive margins, and less need of additional cancer treatments, such as hormone therapy or radiation, than patients who had open surgery. [More]

UNM Cancer Center now adds stereotactic radiosurgery procedure to its list of treatment options

The UNM Cancer Center can now add stereotactic radiosurgery to its growing list of treatment options. This non-invasive outpatient procedure kills tumor cells in the brain in a single treatment. [More]

Avoiding cSMG during radiation therapy is safe in head and neck cancer patients

Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. [More]

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality (VSQ) for up to one year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. [More]
Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. [More]

Humidification of mouth during radiotherapy reduces hospital stay, mucositis in head, neck cancer patients

Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. [More]